Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Tannin inhibits HIV-1 entry by targeting gp41.

Lü L, Liu SW, Jiang SB, Wu SG.

Acta Pharmacol Sin. 2004 Feb;25(2):213-8.

2.

[1,2,6-tri-O-galloyl-beta-D-glucopyranose inhibits gp41-mediated HIV envelope fusion with target cell membrane].

Sun W, Wang HT, Xia CL, Wu SG, Jiang SB, Jiang ZH, Liu SW.

Nan Fang Yi Ke Da Xue Xue Bao. 2008 Jul;28(7):1127-31. Chinese.

3.
4.
6.

HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds.

Liu S, Wu S, Jiang S.

Curr Pharm Des. 2007;13(2):143-62. Review.

PMID:
17269924
7.

[Isolation and characterization of the anti-HIV active component from Eucommia ulmoides].

Lv L, Sun YR, Xu W, Liu SW, Rao JJ, Wu SG.

Zhong Yao Cai. 2008 Jun;31(6):847-50. Chinese.

PMID:
18998566
8.

The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.

Gallo SA, Sackett K, Rawat SS, Shai Y, Blumenthal R.

J Mol Biol. 2004 Jun 25;340(1):9-14.

PMID:
15184018
9.

HIV-1 gp41: mediator of fusion and target for inhibition.

Weiss CD.

AIDS Rev. 2003 Oct-Dec;5(4):214-21. Review.

PMID:
15012000
10.

Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.

Deng Y, Zheng Q, Ketas TJ, Moore JP, Lu M.

Biochemistry. 2007 Apr 10;46(14):4360-9. Epub 2007 Mar 20.

PMID:
17371053
11.

Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.

An T, Ouyang W, Pan W, Guo D, Li J, Li L, Chen G, Yang J, Wu S, Tien P.

Antiviral Res. 2012 Jun;94(3):276-87. doi: 10.1016/j.antiviral.2012.02.014. Epub 2012 Mar 8.

PMID:
22426469
12.

Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.

He Y, Cheng J, Li J, Qi Z, Lu H, Dong M, Jiang S, Dai Q.

J Virol. 2008 Jul;82(13):6349-58. doi: 10.1128/JVI.00319-08. Epub 2008 Apr 16.

13.
15.

Discovery of small molecule fusion inhibitors targeting HIV-1 gp41.

Zhou G, Chu S.

Curr Pharm Des. 2013;19(10):1818-26. Review.

PMID:
23092284
16.

Peptide P5 (residues 628-683), comprising the entire membrane proximal region of HIV-1 gp41 and its calcium-binding site, is a potent inhibitor of HIV-1 infection.

Yu H, Tudor D, Alfsen A, Labrosse B, Clavel F, Bomsel M.

Retrovirology. 2008 Oct 16;5:93. doi: 10.1186/1742-4690-5-93.

18.

A mammalian two-hybrid system-based assay for small-molecular HIV fusion inhibitors targeting gp41.

Shui X, Lu X, Gao Y, Liu C, Ren F, Jiang Q, Zhang H, Zhao B, Zheng Z.

Antiviral Res. 2011 Apr;90(1):54-63. doi: 10.1016/j.antiviral.2011.02.006. Epub 2011 Feb 23.

PMID:
21352856
19.

Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins.

Si Z, Madani N, Cox JM, Chruma JJ, Klein JC, Schön A, Phan N, Wang L, Biorn AC, Cocklin S, Chaiken I, Freire E, Smith AB 3rd, Sodroski JG.

Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):5036-41. Epub 2004 Mar 29.

20.

Supplemental Content

Support Center